GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

The company's revenue jumped 77% in Q3 to reach $401.6 million in Q3 2024, alongside a net income of $75.6 million. It now ...

New research, led by experts at the University of Nottingham, has found that certain types of medication used to treat ...

A new study supports the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to ...

The following is a summary of "Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide ...

There have been a slew of studies recently supporting the notion that the same mechanisms that help folks lose weight ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...